<DOC>
	<DOCNO>NCT00002547</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy bone marrow transplantation may allow doctor give high dos chemotherapy kill cancer cell . PURPOSE : Phase II trial study effectiveness bone marrow transplantation follow combination chemotherapy treat patient acute myeloid leukemia myelodysplastic syndrome .</brief_summary>
	<brief_title>Chemotherapy Bone Marrow Transplantation Treating Patients Acute Myeloid With Leukemia Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : I . Determine overall leukemia-free survival patient acute nonlymphocytic leukemia myelodysplastic syndrome treat busulfan cyclophosphamide ( low-risk patient ) cytarabine , busulfan , cyclophosphamide ( high-risk patient ) follow allogeneic syngeneic bone marrow transplantation . II . Compare therapeutic effect cytoreduction regimen report literature similar patient undergo syngeneic allogeneic marrow transplantation follow cytoreduction include total-body irradiation . III . Determine early late toxic effect produce chemotherapy regimen patient population . OUTLINE : Low-risk patient ( first complete remission ( CR ) achieve CR 1 course chemotherapy ) treat Regimen A . High-risk patient ( second subsequent CR require 1 course chemotherapy achieve first CR myelodysplastic syndrome ) treat Regimen B . All patient undergo diagnostic lumbar puncture prior begin therapy fluid examine CNS disease . Patients receive methotrexate IT along tap . Prior initiation chemotherapy , patient CNS disease present diagnostic lumbar puncture receive methotrexate IT every 2-3 day lumbar puncture show leukemia cell 1 additional dose . Cytoreductive chemotherapy begin 3 day last dose methotrexate . Regimen A : Patients receive oral busulfan every 6 hour day -7 -4 total 16 dos cyclophosphamide IV 2 hour day -3 -2 . Allogeneic bone marrow infuse day 0 . Regimen B : Patients receive oral busulfan every 6 hour day -9 -6 total 16 dos . Patients receive cytarabine IV 1 hour every 12 hour day -5 -4 cyclophosphamide IV 2 hour day -3 -2 . Allogeneic bone marrow infuse day 0 . Graft versus host disease prophylaxis : Patients receive cyclosporine IV continuously day -1 28 follow taper oral cyclosporine day 180 . Patients receive methotrexate IV day 1 , 3 , 6 , 11 . CNS disease prophylaxis : Patients receive 5 dos methotrexate IT weekly beginning day 50 70 . In addition , patient history CNS disease receive 1 dose methotrexate IT monthly 1 year . Patients follow frequently first 100 day , 6 month , 1 year , annually thereafter . PROJECTED ACCRUAL : A total 40 patient accrue study within 2.7 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : The follow hematologic malignancy eligible : Acute nonlymphocytic leukemia one follow category : In complete remission In early relapse Newly diagnose FAB type M6 M7 Myelodysplastic syndrome include : Refractory anemia excessive blast Refractory anemia excessive blast transformation Chronic myelomonocytic leukemia Secondary acute myeloid leukemia Transplantation priority give decrease order : First remission Second remission Third remission Early relapse , priority reduce : Refractory response platelet transfusion Severe infection within 6 week prior referral History major organ pathology insult ( hepatitis , renal damage , pulmonary disease , cystitis , etc . ) CNS disease allow priority status transplantation lower Donor Criteria : Sibling match related/unrelated donor require Donor priority follow : Monozygotic twin Genotypical phenotypical HLAA , B , C , D match Match 2 locus ( A , B , Dr ) haplotype ABOcompatible donor preferred Marrow process eliminate mismatch erythrocyte ABO incompatible In case multiple donor , priority : ABO compatibility Age 18 Same sex No physiologic , psychologic , medical contraindication donation procedure No increase anesthetic risk due preexist illness HIV negative PATIENT CHARACTERISTICS : Age : 6 month 60 year Performance status : No preterminal moribund patient Life expectancy : No severe limit life expectancy due disease leukemia Hematopoietic : See Disease Characteristics Hepatic : Bilirubin great 2.0 mg/dL Transaminases great 3 time normal No severe hepatic disease Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min No severe renal disease No history severe cystitis cyclophosphamide Cardiovascular : LVEF least 50 % No symptomatic cardiac disease Pulmonary : FEV1 FVC least 75 % normal No severe pulmonary disease Other : HIV negative No severe personality disorder severe mental illness No condition ( substance abuse ) would markedly increase morbidity mortality transplantation Criteria hepatic , renal , cardiac , pulmonary function mental illness use initial screen potential candidate ; patient meet criterion may still eligible discretion transplant team PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>untreated childhood acute myeloid leukemia myeloid malignancy</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>childhood acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>childhood acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>childhood acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>childhood acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>childhood acute monoblastic leukemia ( M5a )</keyword>
	<keyword>childhood acute monocytic leukemia ( M5b )</keyword>
	<keyword>childhood acute erythroleukemia ( M6 )</keyword>
	<keyword>childhood acute megakaryocytic leukemia ( M7 )</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>